Abstract

The large size of nanoparticles prevents rapid extravasation from blood vessels and diffusion into tumors. Multimodal imaging uses the physical properties of one modality to validate the results of another. We aim to demonstrate the use of a targeted thin layer-protected ultra-small gold nanoparticles (Au-NPs) to detect cancer in vivo using multimodal imaging with photoacoustic and computed tomography (CT). The thin layer was produced using a mixed thiol-containing short ligands, including MUA, CVVVT-ol, and HS-(CH2)11-PEG4-OH. The gold nanoparticle was labeled with a heterobivalent (HB) peptide ligand that targets overexpression of epidermal growth factor receptors (EGFR) and ErbB2, hereafter HB-Au-NPs. A human xenograft model of esophageal cancer was used for imaging. HB-Au-NPs show spherical morphology, a core diameter of 4.47 ± 0.8 nm on transmission electron microscopy, and a hydrodynamic diameter of 6.41 ± 0.73 nm on dynamic light scattering. Uptake of HB-Au-NPs was observed only in cancer cells that overexpressed EGFR and ErbB2 using photoacoustic microscopy. Photoacoustic images of tumors in vivo showed peak HB-Au-NPs uptake at 8 h post-injection with systemic clearance by ~48 h. Whole-body images using CT validated specific tumor uptake of HB-Au-NPs in vivo. HB-Au-NPs showed good stability and biocompatibility with fast clearance and contrast-enhancing capability for both photoacoustic and CT imaging. A targeted thin layer-protected gold nanoprobe represents a new platform for molecular imaging and shows promise for early detection and staging of cancer.

Highlights

  • Esophageal adenocarcinoma (EAC) is an aggressive disease with a poor 5-year survival rate of between 15–25% [1]

  • The terminal carboxylic acid of mercaptoundecanoic acid (MUA) was activated by an NHS ester and reacted with DBCO-PEG4 -amine

  • The azide functionalized heterobivalent (HB) peptide consists of monomers QRHKPRE, hereafter QRH*, and KSPNPRF, hereafter KSP*, specific for Epidermal growth factor receptors (EGFR) and ErbB2, respectively [18,19,20]

Read more

Summary

Introduction

Esophageal adenocarcinoma (EAC) is an aggressive disease with a poor 5-year survival rate of between 15–25% [1]. This disease is associated with high morbidity and mortality, accurate staging is important to determine the best therapeutic options for patients. Magnetic resonance imaging (MRI), computed tomography (CT), and endoscopic ultrasound are frequently used for cancer staging. These imaging modalities detect grossly visible anatomic abnormalities, such as the presence of a mass, to detect cancer, and are not sensitive to small or subtle lesions.

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call